Catalyst Pharmaceuticals announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome, LEMS, Awareness Day. This landmark event, now officially observed annually on March 30th, signifies a meaningful milestone for the LEMS community. The chosen date holds profound historical significance, coinciding with the publication of Dr. Edward Lambert and Dr. Lee Eaton’s pioneering research on LEMS, which has greatly advanced the understanding and treatment of this rare neuromuscular disorder. “Creating an awareness day for LEMS is a huge win for our community,” said Price Wooldridge, Founder and Board Member of the LEMS Family Association. “This brings us one step closer to our goal, improving the awareness of our rare condition in the larger population. We couldn’t be more thrilled to celebrate the milestone of this first LEMS Awareness Day together.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
- Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
- Catalyst Pharmaceuticals management to meet with Oppenheimer
- Catalyst Pharmaceuticals initiated with a Buy at Citi
- Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
